Selective Estrogen Receptor Alpha Agonist GTx-758 Decreases Testosterone with Reduced Side Effects of Androgen Deprivation Therapy in Men with Advanced Prostate Cancer

Abstract Background A need remains for new therapeutic approaches for men with advanced prostate cancer, particularly earlier in the disease course. Objective To assess the ability of an oral selective estrogen receptor α agonist (GTx-758) to lower testosterone concentrations compared with leuprolid...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European urology 2015-02, Vol.67 (2), p.334-341
Hauptverfasser:	Yu, Evan Y, Getzenberg, Robert H, Coss, Christopher C, Gittelman, Marc M, Keane, Thomas, Tutrone, Ronald, Belkoff, Laurence, Given, Robert, Bass, Joel, Chu, Franklin, Gambla, Michael, Gaylis, Franklin, Bailen, James, Hancock, Michael L, Smith, Jordan, Dalton, James T, Steiner, Mitchell S
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Aged Aged, 80 and over Antineoplastic Agents, Hormonal - administration & dosage Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - therapeutic use Benzamides - administration & dosage Benzamides - adverse effects Benzamides - therapeutic use Biomarkers, Tumor - blood Bone turnover Delayed-Action Preparations Down-Regulation Estrogen receptor Free testosterone GTx-758 Humans Leuprolide Leuprolide - administration & dosage Leuprolide - adverse effects Leuprolide - therapeutic use Male Middle Aged Neoplasms, Hormone-Dependent - blood Neoplasms, Hormone-Dependent - drug therapy Neoplasms, Hormone-Dependent - pathology Prospective Studies Prostate cancer Prostatic Neoplasms - blood Prostatic Neoplasms - drug therapy Prostatic Neoplasms - pathology Selective Estrogen Receptor Modulators - administration & dosage Selective Estrogen Receptor Modulators - adverse effects Selective Estrogen Receptor Modulators - therapeutic use Sex hormone-binding globulin Testosterone - blood Treatment Outcome United States Urology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!